SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aratana Therapeutics, Inc. (PETX)

NEW YORK, Feb. 6, 2017

The investigation concerns whether Aratana and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation drug.  Aratana informed shareholders that it "now anticipates that ENTYCE . . . will be commercially available by late 2017" and that the CVM's request was "in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale."  Following this news, Aratana stock has dropped as much as $1.53 per share, or 19.05%, to a low of $6.50 during intraday trading on February 6, 2017.

If you are aware of any facts relating to this investigation, or purchased Aratna shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/petx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-aratana-therapeutics-inc-petx-300402562.html